Medicare Is About to Spend $100 Million on “Functional Medicine.”

Key Takeaways

• CMS Innovation Center allocates $100M to MAHA ELEVATE
• Program funds up to 30 organizations for lifestyle interventions
• Functional medicine inclusion raises evidence‑based concerns
• Medicare already covers proven nutrition, exercise, and rehab programs
• Strong oversight required to avoid funding pseudoscientific wellness

Summary

The CMS Innovation Center has launched the MAHA ELEVATE pilot, earmarking $100 million to award grants to up to 30 organizations over three years beginning September 2026. The program aims to test whole‑person health approaches—including nutrition, exercise, sleep and stress management—and explicitly invites functional‑medicine providers. While Medicare already funds evidence‑based lifestyle programs, critics warn that the inclusion of loosely defined functional medicine could channel taxpayer dollars into unproven wellness services. The initiative’s success hinges on rigorous evaluation and clear oversight.

Pulse Analysis

Medicare’s chronic disease burden drives policymakers to seek preventive solutions that lower costs while improving quality of life. The MAHA ELEVATE initiative, funded through the ACA‑created Innovation Center, represents a $100 million gamble on "whole‑person" health models. By targeting nutrition, exercise, sleep and stress reduction, the program aligns with a broader shift toward value‑based care, where outcomes—not volume—determine reimbursement. Yet the pilot arrives at a time when Medicare already supports evidence‑based programs such as the Diabetes Prevention Program, cardiac rehabilitation, and medical nutrition therapy, raising questions about redundancy and fiscal efficiency.

Functional medicine, a loosely regulated wellness sector, blends legitimate lifestyle advice with unvalidated supplements, extensive lab testing, and individualized "root‑cause" narratives. Proponents argue it personalizes care, but critics highlight the lack of randomized trials and the high out‑of‑pocket costs for patients. By explicitly inviting functional‑medicine providers, MAHA ELEVATE blurs the line between scientifically vetted interventions and commercial wellness offerings. This inclusion could attract organizations that prioritize branding over measurable health outcomes, potentially diluting the program’s intended evidence‑generation purpose.

The ultimate impact of MAHA ELEVATE will depend on the rigor of its evaluation framework and the transparency of its funding criteria. Robust oversight mechanisms—such as independent data monitoring committees and predefined success metrics—are essential to ensure taxpayer dollars advance proven preventive strategies rather than subsidize speculative treatments. Should the pilot yield clear cost‑savings and improved patient metrics, it may pave the way for broader Medicare adoption of integrated lifestyle models. Conversely, failure to demonstrate efficacy could reinforce skepticism toward federally backed wellness initiatives and prompt tighter regulations on functional‑medicine claims.